Biotech News
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results
neurocrine.gcs-web.com2026-05-05 20:09 EST
Total First-Quarter 2026 Net Product Sales of $811.0 Million, An Increase of 44% Year-Over-Year Announced Definitive Agreement to Acquire Soleno Therapeutics, Including VYKAT TM XR (diazoxide choline) for the Treatment of Hyperphagia in Prader-Willi Syndrome Expected to Close in Q2 2026 Initiated